Head: Patrizia Vici, MD
STAFF

Clinical and Research Activity

All the activities, both clinical and scientific, of the UOSD Sperimentazioni di fase IV (Phase IV Clinical Unit) are focused on breast cancer treatment and follow up.

The activity of the UOSD is mainly dedicated to observational, retro-prospective, multicenter studies on breast cancer, aiming at evaluating some aspects frequently ignored by registrative trials.

There is also a strong collaboration with experimental department for many studies, most of them coordinated by the UOSD in collaboration with other oncologic centres.

In the neo/adjuvant setting: Triskele study, in Her2 positive tumors,  and the Care study, in the postneoadjuvant setting, are published on  international journals,  whereas Hippo SAB, NeoTAZ, NeoCarbo, PHOBOS and a study of prognostic relevance of DNA Damage biomarkers in elderly patients undergoing neoadjuvant hormone therapy, as well ATD study  in HER2 positive post-neoadiuvant setting,  are still ongoing.

In the advanced setting: the ongoing STEP trial, focused on the therapeutic algorithm of HER2+ Bca, was awarded by the Ministry of Health; moreover, INDACO, PALBOSS , REPER, TETRIS , SePher , PANHER studies and many other studies, all multicentric involving more than sixty italian  oncologic centres, are now closed and published on international journals.

Furthermore, we actively adhered with a non-coordinating role to the following trials: NATALEE, HERMIONE 8, HERMIONE 9,  Neogene, VIP, a retrospective study on Trastuzumab-related cardiotoxicity, SEQUERPLUS, VasMUss, MARIO, POSITIVE, BioItaLEE, VICTOR3, VICTOR6 COMPLEEMENT-1, IMPASSION 131, EVA, ECHO, BRIDE, TiLT, GIM16-FEVEX, HERBA, ESEMPiO, eve-exe study, GOIRC , Vanessa, Portent, Identity, Selebrec,  Europa, EMBER4, eVERA, and others.

Many studies involve innovative oncologic drugs, in luminal, Her2 positive and triple negative breast cancer type. Among them, Brawe study, Ember IV, Olema, eVERA, Sarelife, Bioprosa,  Lidera, Bo41843, and many others.

 The Papers on breast cancer published on international journals in the last years  are 92.